The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Open accessAbstract
The management of dementia has changed since the development of new antidementia drugs. The benefits observed in Alzheimer's disease (AD) with selective cholinergic transmission treatments are mainly symptomatic, without clear evidence of neuroprotection. The hypothesis that glutamate-mediated neurotoxicity is involved in the pathogenesis of AD is finding increasingly more acceptance in the scientific community. Glutamate receptors are overactive, and N-methyl-D-aspartate (NMDA) receptor antagonists have therapeutic potential for the treatment of AD and other neurological disorders. Memantine is a noncompetitive NMDA antagonist that is considered a neuroprotective drug. Memantine's capacity has been demonstrated in preclinical studies, and it is considered a useful symptomatic treatment for AD. Memantine has been shown to benefit cognition, function, and global outcome in patients with moderate to severe AD, and it is currently approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe AD. Recently, memantine has also demonstrated efficacy in the initial stages of AD, although FDA authorization is pending. This review highlights the important pharmacological and clinical aspects of memantine, as well as some basic mechanisms mediating glutamatergic neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dizziness, agitation, hallucinations, headache, and exhaustion were the most common symptoms that arose in clinical trials.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Molinuevo et al., 2005
In the citing paper
“Memantine (a glutamate receptor antagonist) is a promising drug molecule that inhibits excess glutamate activity, which is important for memory and learning.99”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Excitotoxity and the NMDA receptor
Rothman, S. M., & Olney, J. W. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90177-9 · Cited by 1,052
The Biochemistry of Memory: A New and Specific Hypothesis
LYNCH, G. S., & Baudry, M. (1984) · Science · doi:10.1126/science.6144182 · Cited by 1,041
The question of familial meningiomas and schwannomas:
King, A. A., & Gutmann, D. H. (2000) · Neurology · doi:10.1212/wnl.54.1.4 · Cited by 814
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Excitotoxicity and the NMDA receptor -- still lethal after eight years
Rothman, S. M. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508
Research works printed but not linked: 7
- Lobo A, 2000, Neurology, 54, S4
- Launer LJ, 2000, Neurology, 54, S1
- Kilpatrick GJ, 2002, Curr Opin Investig Drugs, 3, 798
- Danysz W, 1995, Drug News Perspect, 8, 261
- Landfield PW, 1988, Long-Term Potentiation: A Debate of Current Issues
- Pantev M, 1993, Zeitschrift Gentopsychol Psychiatrie, 6, 103
- Reisberg B, 2003, Eur Neuropsychopharmacol, 13, S388
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Calcium Signaling and Amyloid Toxicity in Alzheimer Disease
Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 426
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 320
Blaylock, R. L., & Maroon, J. C. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.83391 · Cited by 212
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Metadata
- Authors
- Molinuevo, J. L., Lladó, A., & Rami, L.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2005-03
- Volume
- 20
- Issue
- 2
- Pages
- 77-85
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- PMC
- PMC10833270
- OpenAlex
- W2140959932
- Cited by
- 125
- References
- 58
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 2 · 2015: 8 · 2014: 5 · 2013: 8 · 2012: 4
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- memantine, Alzheimer's disease, dementia, glutamate excitotoxicity, NMDA receptor antagonists, neuroprotection, symptomatic treatment, clinical efficacy
- MeSH terms
- Animals, Clinical Trials as Topic, Dementia, Drug Evaluation, Preclinical, Humans, Memantine, Molecular Structure, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Glutamic Acid, Amino Acid Transport System X-AG
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
